(±)-1-Amino-cis-3-phosphonocyclohexanecarboxylic acid

Discontinued Product

(±)-1-Amino-cis-3-phosphonocyclohexanecarboxylic acid (Cat. No. 0191) has been withdrawn from sale for commercial reasons.
Cat.No. 0191 - (±)-1-Amino-cis-3-phosphonocyclohexanecarboxylic acid | CAS No. 103439-20-9
Description: Analogue of DL-AP4 (0101)
Datasheet
Citations
Reviews
Literature

Biological Activity

Conformationally restricted analogue of AP4.

Technical Data

M. Wt 223.17
Storage Store at RT
CAS Number 103439-20-9

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Product Datasheets

Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service

References

References are publications that support the biological activity of the product.

Crooks et al (1986) Cyclic analogues of 2-amino-4-phosphonobutanoic acid (AP4) and their inhibition of hippocampal excitatory transmission and displacement of [3H]AP4 binding. J.Med.Chem. 29 1988 PMID: 3020251

Keywords: (±)-1-Amino-cis-3-phosphonocyclohexanecarboxylic acid, (±)-1-Amino-cis-3-phosphonocyclohexanecarboxylic acid supplier, Non-selective, mGlu, 0191, Tocris Bioscience

Citations for (±)-1-Amino-cis-3-phosphonocyclohexanecarboxylic acid

Citations are publications that use Tocris products.

Currently there are no citations for (±)-1-Amino-cis-3-phosphonocyclohexanecarboxylic acid.

Reviews for (±)-1-Amino-cis-3-phosphonocyclohexanecarboxylic acid

There are currently no reviews for this product. Be the first to review (±)-1-Amino-cis-3-phosphonocyclohexanecarboxylic acid and earn rewards!

Have you used (±)-1-Amino-cis-3-phosphonocyclohexanecarboxylic acid?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


GPCR

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Secretin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Pain

Pain Research Product Guide

A collection of over 250 products for pain research, the guide includes research tools for the study of:

  • Nociception
  • Ion Channels
  • G-Protein-Coupled Receptors
  • Intracellular Signaling
Metabotropic Glutamate Receptors

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Epilepsy

Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.

Learning & Memory

Learning & Memory Poster

Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.